Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Values First Advisors Inc.

Values First Advisors Inc. lowered its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 24.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,249 shares of the biopharmaceutical company’s stock after selling 6,698 shares during the quarter. Values First Advisors Inc.’s holdings in Sage Therapeutics were worth $115,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its stake in Sage Therapeutics by 66.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 4,672 shares during the last quarter. Creative Planning acquired a new stake in shares of Sage Therapeutics in the 3rd quarter valued at about $88,000. Empowered Funds LLC acquired a new stake in shares of Sage Therapeutics in the 4th quarter valued at about $91,000. Quest Partners LLC lifted its position in shares of Sage Therapeutics by 56.3% during the third quarter. Quest Partners LLC now owns 18,381 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 6,618 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in Sage Therapeutics in the third quarter worth about $146,000. Institutional investors own 99.22% of the company’s stock.

Wall Street Analysts Forecast Growth

SAGE has been the topic of several research reports. Stifel Nicolaus cut their price objective on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating on the stock in a research note on Monday, December 16th. Piper Sandler dropped their price target on Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, January 2nd. Royal Bank of Canada upgraded Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price objective on the stock in a research note on Thursday, November 21st. Truist Financial lowered their target price on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating for the company in a research note on Wednesday, October 30th. Finally, TD Cowen reduced their price target on shares of Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Thursday, November 21st. Three research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Sage Therapeutics presently has an average rating of “Hold” and a consensus price target of $9.65.

Sage Therapeutics Stock Performance

Shares of NASDAQ:SAGE opened at $7.16 on Thursday. The firm’s 50 day moving average is $6.34 and its two-hundred day moving average is $6.93. Sage Therapeutics, Inc. has a 52 week low of $4.62 and a 52 week high of $27.39.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. On average, sell-side analysts predict that Sage Therapeutics, Inc. will post -6.46 earnings per share for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.